Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study
NCT ID: NCT01498055
Last Updated: 2012-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2011-12-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
NCT07035860
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
NCT03505515
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
NCT01249066
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
NCT07250360
Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients
NCT02113852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CIK therapy group
No interventions assigned to this group
control group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary lung cancer patients after chemotherapy or radiation therapy;
* Primary lung cancer patients after targeted therapy;
* Primary lung cancer patients with lung function can not accept operation or unwilling to operation;
* Primary lung cancer recurrence or surgery can't complete resection;
* Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.);
* No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases;
* Patients Voluntary attempt, and informed consent.
Exclusion Criteria
* Cachexia; or other deadly diseases;
* Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;
* Active infection;
* Pregnant or lactating women
* At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);
* Now or recently will join another experimental clinical study ;
* Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Military Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gong Liang
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiangdong Zhou
Role: STUDY_CHAIR
Southwest Hospital Third Military University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liang Gong
Chongqing, Chong Qing, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLiang
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.